RS102895 NEW
| Price | $59 | $97 | $178 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: RS102895 | CAS No.: 300815-41-2 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | RS102895 |
| Description | RS102895 is a potent CCR2 antagonist (IC50: 360 nM) and shows no effect on CCR1. |
| In vitro | RS102895 also inhibits human α1a, α1d receptors, rat brain cortex 5HT1a receptor in cells with IC50s of 130, 320, 470 nM, respectively. RS102895 suppresses wild type and D284N mutant MCP-1 receptor (IC50, 550 nM and 568 nM, respectively), less potently inhibits D284A MCP-1 receptor (IC50, 1892 nM), and has no effects on E291A, E291Q, D284A/E291A or D284N/E291Q (IC50, >100,000?nM) [1]. RS102895 ameliorates the increased extracellular matrix protein expression by inhibition of CCR2 at 10 μM and obviously blocks fibronectin and type IV collagen protein expression in high glucose-stimulated mesangial cells (MCs) at 1 or 10 μM. RS102895 (10 μM) also abrogate the increased TGF-1 levels in MCs treated with MCP-1 [2]. |
| In vivo | RS102895 at a concentration of 3 g/L progressively lowers the pain threshold in rats experiencing bone cancer pain (BCP) from days 3 to 9 post-surgery through intrathecal administration, with the threshold rising again after day 12. Additionally, RS102895 effectively alters the expression levels of NR2B, nNOS, and SIGIRR in the spinal cord. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 15 mg/mL (38.42 mM) |
| Keywords | CC chemokine receptor | CCR | Inhibitor | RS 102895 | RS-102895 | RS102895 | inhibit |
| Inhibitors Related | AZD2098 | MLN-3897 TFA | Artemotil | CCR2 antagonist 5 | INCB-9471 | CCR3 antagonist 1 | Maraviroc | BMS-817399 | PF-4136309 | Pirfenidone | Vercirnon | CCR6 antagonist 1 |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Chemokine Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $40.00/2mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-07 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY